




**CSA
Group**

Z902-15

Blood and blood components



Legal Notice for Standards

Canadian Standards Association (operating as “CSA Group”) develops standards through a consensus standards development process approved by the Standards Council of Canada. This process brings together volunteers representing varied viewpoints and interests to achieve consensus and develop a standard. Although CSA Group administers the process and establishes rules to promote fairness in achieving consensus, it does not independently test, evaluate, or verify the content of standards.

Disclaimer and exclusion of liability

This document is provided without any representations, warranties, or conditions of any kind, express or implied, including, without limitation, implied warranties or conditions concerning this document’s fitness for a particular purpose or use, its merchantability, or its non-infringement of any third party’s intellectual property rights. CSA Group does not warrant the accuracy, completeness, or currency of any of the information published in this document. CSA Group makes no representations or warranties regarding this document’s compliance with any applicable statute, rule, or regulation.

IN NO EVENT SHALL CSA GROUP, ITS VOLUNTEERS, MEMBERS, SUBSIDIARIES, OR AFFILIATED COMPANIES, OR THEIR EMPLOYEES, DIRECTORS, OR OFFICERS, BE LIABLE FOR ANY DIRECT, INDIRECT, OR INCIDENTAL DAMAGES, INJURY, LOSS, COSTS, OR EXPENSES, HOWSOEVER CAUSED, INCLUDING BUT NOT LIMITED TO SPECIAL OR CONSEQUENTIAL DAMAGES, LOST REVENUE, BUSINESS INTERRUPTION, LOST OR DAMAGED DATA, OR ANY OTHER COMMERCIAL OR ECONOMIC LOSS, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE), OR ANY OTHER THEORY OF LIABILITY, ARISING OUT OF OR RESULTING FROM ACCESS TO OR POSSESSION OR USE OF THIS DOCUMENT, EVEN IF CSA GROUP HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, INJURY, LOSS, COSTS, OR EXPENSES.

In publishing and making this document available, CSA Group is not undertaking to render professional or other services for or on behalf of any person or entity or to perform any duty owed by any person or entity to another person or entity. The information in this document is directed to those who have the appropriate degree of experience to use and apply its contents, and CSA Group accepts no responsibility whatsoever arising in any way from any and all use of or reliance on the information contained in this document.

CSA Group is a private not-for-profit company that publishes voluntary standards and related documents. CSA Group has no power, nor does it undertake, to enforce compliance with the contents of the standards or other documents it publishes.

Intellectual property rights and ownership

As between CSA Group and the users of this document (whether it be in printed or electronic form), CSA Group is the owner, or the authorized licensee, of all works contained herein that are protected by copyright, all trade-marks (except as otherwise noted to the contrary), and all inventions and trade secrets that may be contained in this document, whether or not such inventions and trade secrets are protected by patents and applications for patents. Without limitation, the unauthorized use, modification, copying, or disclosure of this document may violate laws that protect CSA Group’s and/or others’ intellectual property and may give rise to a right in CSA Group and/or others to seek legal redress for such use, modification, copying, or disclosure. To the extent permitted by licence or by law, CSA Group reserves all intellectual property rights in this document.

Patent rights

Attention is drawn to the possibility that some of the elements of this standard may be the subject of patent rights. CSA Group shall not be held responsible for identifying any or all such patent rights. Users of this standard are expressly advised that determination of the validity of any such patent rights is entirely their own responsibility.

Authorized use of this document

This document is being provided by CSA Group for informational and non-commercial use only. The user of this document is authorized to do only the following:

If this document is in electronic form:

- load this document onto a computer for the sole purpose of reviewing it;
- search and browse this document; and
- print this document if it is in PDF format.

Limited copies of this document in print or paper form may be distributed only to persons who are authorized by CSA Group to have such copies, and only if this Legal Notice appears on each such copy.

In addition, users may not and may not permit others to

- alter this document in any way or remove this Legal Notice from the attached standard;
- sell this document without authorization from CSA Group; or
- make an electronic copy of this document.

If you do not agree with any of the terms and conditions contained in this Legal Notice, you may not load or use this document or make any copies of the contents hereof, and if you do make such copies, you are required to destroy them immediately. Use of this document constitutes your acceptance of the terms and conditions of this Legal Notice.



Standards Update Service

Z902-15

December 2015

Title: *Blood and blood components*

To register for e-mail notification about any updates to this publication

- go to shop.csa.ca
- click on **CSA Update Service**

The **List ID** that you will need to register for updates to this publication is **2423931**.

If you require assistance, please e-mail techsupport@csagroup.org or call 416-747-2233.

Visit CSA Group's policy on privacy at www.csagroup.org/legal to find out how we protect your personal information.

Z902-15
Blood and blood components



™A trade-mark of the Canadian Standards Association, operating as "CSA Group"

*Published in December 2015 by CSA Group
A not-for-profit private sector organization
178 Rexdale Boulevard, Toronto, Ontario, Canada M9W 1R3*

*To purchase standards and related publications, visit our Online Store at shop.csa.ca
or call toll-free 1-800-463-6727 or 416-747-4044.*

ISBN 978-1-4883-0056-1

*© 2015 CSA Group
All rights reserved. No part of this publication may be reproduced in any form whatsoever
without the prior permission of the publisher.*

Contents

Technical Committee on Blood and Blood Components	7
Preface	10
0 Introduction	11
1 Scope	11
2 Reference publications	13
3 Definitions and abbreviations	14
3.1 Definitions	14
3.2 Abbreviations	22
4 General	23
4.1 Policies	23
4.2 Operating procedures	23
4.2.1 General	23
4.2.2 Development, approval, and distribution of operating procedures	24
4.2.3 Document control	25
4.2.4 Storage and retention	26
4.3 Personnel	27
4.3.1 General	27
4.3.2 Training	28
4.3.3 Competency assessment and proficiency testing	28
4.3.4 Records	29
4.3.5 Specific requirements for blood centres	29
4.3.6 Specific requirements for transfusion services	29
4.4 Transfusion committee	30
4.5 Health and safety	30
4.5.1 General	30
4.5.2 Biological safety	30
4.5.3 Chemical safety	31
4.5.4 Radiation safety	31
4.6 Quality system	31
4.6.1 General	31
4.6.2 Corrective action and preventative measures	32
4.6.3 Periodic review and audits	33
4.6.4 Contractors, subsidiary facilities, and mobile clinic sites	33
4.7 Process control	33
5 Donor selection for allogeneic blood collection	35
5.1 General	35
5.2 Criteria to protect the donor	36
5.2.1 General	36
5.2.2 Age	36
5.2.3 Weight	37

- 5.2.4 Donation interval 37
- 5.2.5 Blood pressure 37
- 5.2.6 Hemoglobin and hematocrit 37
- 5.2.7 Current or past medical illness 37
- 5.2.8 Pregnancy 37
- 5.3 Criteria to protect the recipient 38
 - 5.3.1 General 38
 - 5.3.2 Personal or family history of Creutzfeldt-Jakob disease (CJD) 39
 - 5.3.3 Travel to Europe, Saudi Arabia, or the United Kingdom since 1980 39
 - 5.3.4 Receipt of blood components, human tissues, or organs 40
 - 5.3.5 Ingestion of medications that alter platelet function 40
 - 5.3.6 Immunizations and vaccinations 40
 - 5.3.7 Cancer 41
 - 5.3.8 Infectious diseases 41
 - 5.3.9 Presence of risk factors for transmissible diseases 41
 - 5.3.10 Malaria 42
 - 5.3.11 Other protozoan diseases 43

6 Collection of blood components for transfusion 43

- 6.1 General 43
- 6.2 Collection procedure 44
- 6.3 Storage and transportation from collection site 45
 - 6.3.1 Storage 45
 - 6.3.2 Transportation 45
 - 6.3.3 Blood components prepared at the collection site 45
- 6.4 Therapeutic phlebotomy 46

7 Preparation of blood components 46

- 7.1 General 46
- 7.2 Open system 46
- 7.3 Sterile connecting device 47
- 7.4 Pre-storage leukoreduction 47
- 7.5 Red blood cell components 48
 - 7.5.1 Red blood cells 48
 - 7.5.2 Red blood cells – frozen 48
 - 7.5.3 Red blood cells – washed 49
 - 7.5.4 Red blood cells – IgA deficient 50
 - 7.5.5 Red blood cells – rejuvenated 50
 - 7.5.6 Red blood cells – low volume 50
- 7.6 Plasma components 51
 - 7.6.1 General 51
 - 7.6.2 Fresh frozen plasma and frozen plasma 51
 - 7.6.3 Cryoprecipitate 51
 - 7.6.4 Cryosupernatant plasma 52
- 7.7 Platelets and platelets–pheresis 53
- 7.8 Granulocytes 53
- 7.11 Pooled or mixed components 54
- 7.12 Irradiation of blood components 54
- 7.13 Quality control of allogeneic blood components 55

8	Testing and labelling of blood components	55
8.1	General	55
8.2	ABO and Rh groups	56
8.3	Tests for detecting clinically significant red cell antibodies	57
8.4	Tests intended to prevent disease transmission	57
8.5	Visual inspection	59
8.6	Labelling	59
8.6.1	General	59
8.6.2	Blood component identification	60
8.6.3	Labelling at collection or preparation	60
8.6.4	Labelling prior to release into inventory at the blood centre	61
8.6.5	Special labelling requirements	61
8.6.6	Circular of information	61
9	Release, storage, packing, and transportation of blood components	62
9.1	General	62
9.2	Release from the blood centre	62
9.3	Release of untested blood components	62
9.4	Storage	63
9.5	Packing and transportation	64
9.5.1	General	64
9.5.2	Facility-to-facility	64
9.5.3	Within a facility	66
10	Requests, pre-transfusion testing, selection of components, and acceptance criteria	66
10.1	General	66
10.2	Requests	66
10.3	Recipient blood samples	67
10.4	Testing of recipient blood	68
10.5	Testing of donor blood	69
10.6	Crossmatching	69
10.6.1	General	69
10.6.2	Serological crossmatch	69
10.6.3	Computer crossmatch	70
10.7	Selection of blood components	71
10.8	Pooled or mixed components	72
10.9	Special circumstances	72
10.9.1	Infants under 4 months	72
10.9.2	Massive transfusion	73
10.9.3	Emergency transfusion	74
10.10	Acceptability	74
11	Transfusion of blood components	75
11.1	Conditions of transfusion	75
11.1.1	General	75
11.1.2	Records system	75
11.2	Information to recipients, including informed consent	76
11.3	Identification of recipient	77
11.4	Transfusion	77

- 11.5 Warming 79
- 11.6 Cellular blood components selected or processed to reduce the risk of CMV transmission 79
- 11.7 Irradiated blood components 79
- 11.8 Granulocytes 80
- 11.9 Rh-immune globulin (RhIG) 80

- 12 Autologous blood collection and transfusion 81**
 - 12.1 General 81
 - 12.2 Criteria for donation 82
 - 12.3 Testing and labelling 82
 - 12.3.1 Testing 82
 - 12.3.2 Labelling 83
 - 12.4 Pre-transfusion testing and transfusion 83
 - 12.5 Perioperative collection 84

- 13 Apheresis donation 85**
 - 13.1 General 85
 - 13.2 Collection 87
 - 13.3 Additional requirements for each type of component collected 88
 - 13.3.1 Plasma collected by apheresis 88
 - 13.3.2 Platelets collected by apheresis 90
 - 13.3.3 Red blood cells collected by apheresis 91
 - 13.3.4 Leukocytes collected by apheresis 91
 - 13.4 Therapeutic apheresis 91

- 14 Transfusion service responsibilities regarding blood products used in the facility 92**
 - 14.1 General 92
 - 14.2 Records 92
 - 14.3 Requests 92
 - 14.4 Preparation for administration 93
 - 14.5 Administration 93
 - 14.6 Storage and transportation 93
 - 14.7 Home administration 94
 - 14.8 Adverse events 94

- 15 Directed donations and designated donations 94**
 - 15.1 Directed donations 94
 - 15.2 Designated donations 95

- 16 Pre-assessed donor programs 96**
 - 16.1 General 96
 - 16.2 Health care facility 96
 - 16.3 Donors 97
 - 16.4 Staff 97
 - 16.5 Labelling 97
 - 16.6 Testing 98

- 17 Home transfusion 98**
 - 17.1 General 98

- 17.2 Recipient selection 99
- 17.3 Informed consent 99
- 17.4 Pre-transfusion testing and selection of components 99
- 17.5 Transportation 99
- 17.6 Administration 100
- 17.7 Disposal of biohazardous waste 100

- 18 Adverse events 100**
 - 18.1 General 100
 - 18.2 Identifying, evaluating, and reporting 101
 - 18.3 Suspected hemolytic transfusion reactions 102
 - 18.4 Suspected bacterial sepsis 102
 - 18.5 Traceback in response to other transfusion-transmissible infections 103

- 19 Removal of unsafe components and donors from the blood supply 104**
 - 19.1 Post-donation information 104
 - 19.2 Recall of allogeneic donations found positive for transmissible disease agents 104
 - 19.3 Lookback 105
 - 19.4 Recall procedure 106

- 20 Record management 107**
 - 20.1 General 107
 - 20.2 Blood donation 109
 - 20.3 Blood component preparation 110
 - 20.4 Final product 110
 - 20.5 Distribution 111
 - 20.6 Storage, retention, and archiving 111
 - 20.6.1 General 111
 - 20.6.2 Records of donors and donor blood components 111
 - 20.6.3 Records of recipients 112
 - 20.6.4 Other records 113
 - 20.7 Product complaints, recalls, and corrective action 113

- 21 Computer systems 114**
 - 21.1 General 114
 - 21.2 Computer system description and documentation 114
 - 21.3 Computer system validation and periodic testing 115
 - 21.4 Change control 115
 - 21.5 Staff qualification 115
 - 21.6 Records 116

- 22 Buildings and facilities 117**
 - 22.1 General 117
 - 22.2 Blood component processing and testing areas 118
 - 22.3 Sanitation program 118
 - 22.4 Mobile sites 119
 - 22.5 Receipt and storage of incoming goods, supplies, and materials 119

- 23 Mechanical equipment 119**
 - 23.1 General 119

23.2	New equipment	120
23.3	Calibration and performance verification	120
23.4	Maintenance	121
23.5	Repairs	121

Annex A (informative)	Summary of significant changes in the third edition	135
Annex B (informative)	French equivalent of terms defined in Clause 3	142

Technical Committee on Blood and Blood Components

G. Delage	Héma-Québec, Saint-Laurent, Québec <i>Category: Procurement and Supply</i>	<i>Chair</i>
M. Hamilton	Nova Scotia Provincial Blood Coordinating Program, Halifax, Nova Scotia <i>Category: Government and/or Regulatory Authority Representing the Canadian Blood Services Provincial/ Territorial Blood Liaison Committee</i>	<i>Vice-Chair</i>
F. Agbanyo	Health Canada, Ottawa, Ontario	<i>Associate</i>
N. Barkat	Health Canada, Ottawa, Ontario <i>Category: Government and/or Regulatory Authority</i>	
S. Cassie	Alberta Health, Edmonton, Alberta <i>Category: Government and/or Regulatory Authority</i>	
C. Colavecchia	Sunnybrook Health Sciences Centre, Toronto, Ontario <i>Category: User/General Interest</i>	
M. Collins	Government of Newfoundland and Labrador, St. John's, Newfoundland and Labrador <i>Category: Government and/or Regulatory Authority</i>	
K. Eckert	Victoria Hospital — London Health Science Centre, London, Ontario <i>Category: User/General Interest</i>	
S. Feenstra	Vancouver Coastal Health, Vancouver, British Columbia <i>Category: User/General Interest</i>	
M. Gauthier	Ministère de la Santé et des Services sociaux, Montréal, Québec <i>Category: Government and/or Regulatory Authority</i>	

L. Gillham-Eisen	Health Canada, Ottawa, Ontario	<i>Associate</i>
M. Goldman	Canadian Blood Services, Ottawa, Ontario <i>Category: Procurement and Supply</i>	
N. Heddle	McMaster University, Hamilton, Ontario <i>Category: Government and/or Regulatory Authority Representing the Canadian Blood Services Provincial/ Territorial Blood Liaison Committee</i>	
C. Hyson	Public Health Agency of Canada, Ottawa, Ontario	<i>Associate</i>
D. Lepine	Health Canada Medical Devices Bureau, Ottawa, Ontario	<i>Associate</i>
Y. Lin	Sunnybrook Health Sciences Centre, Toronto, Ontario <i>Category: User/General Interest</i>	
S. Nahirniak	Alberta Health Services Edmonton, Edmonton, Alberta <i>Category: User/General Interest</i>	
E. Nunes	American Association of Blood Banks, Bethesda, Maryland, U.S.A.	<i>Associate</i>
S. O'Brien	Canadian Blood Services, Ottawa, Ontario <i>Category: Procurement and Supply</i>	
D. Page	Canadian Hemophilia Society, La Durantaye, Québec <i>Category: User/General Interest</i>	
T. Poirier	Canadian Blood Services, Ottawa, Ontario <i>Category: Procurement and Supply</i>	
G. Polnicky	Health Canada, Ottawa, Ontario <i>Category: Government and/or Regulatory Authority</i>	

N. Robitaille	CHU Sainte-Justine, Montréal, Québec <i>Category: User/General Interest</i>	
L. Stevens	Neutropenia Support Association Inc, Winnipeg, Manitoba <i>Category: User/General Interest</i>	
S. Thibault	Héma-Québec, Saint-Laurent, Québec <i>Category: Procurement and Supply</i>	
J. Wallace	Health Canada, Ottawa, Ontario <i>Category: Government and/or Regulatory Authority</i>	
J. Kraegel	CSA Group, Toronto, Ontario	<i>Project Manager</i>

Preface

This is the third edition of CSA Z902, *Blood and blood components*. It supersedes the previous editions published in 2010 and 2004.

See Annex A for a list of major changes to this edition.

This Standard was prepared by the Technical Committee on Blood and Blood Components, under the jurisdiction of the Strategic Steering Committee on Health Care Technology, and has been formally approved by the Technical Committee.

Notes:

- 1) *Use of the singular does not exclude the plural (and vice versa) when the sense allows.*
- 2) *Although the intended primary application of this Standard is stated in its Scope, it is important to note that it remains the responsibility of the users of the Standard to judge its suitability for their particular purpose.*
- 3) *This Standard was developed by consensus, which is defined by CSA Policy governing standardization — Code of good practice for standardization as “substantial agreement. Consensus implies much more than a simple majority, but not necessarily unanimity”. It is consistent with this definition that a member may be included in the Technical Committee list and yet not be in full agreement with all clauses of this Standard.*
- 4) *To submit a request for interpretation of this Standard, please send the following information to inquiries@csagroup.org and include “Request for interpretation” in the subject line:*
 - a) *define the problem, making reference to the specific clause, and, where appropriate, include an illustrative sketch;*
 - b) *provide an explanation of circumstances surrounding the actual field condition; and*
 - c) *where possible, phrase the request in such a way that a specific “yes” or “no” answer will address the issue.*

Committee interpretations are processed in accordance with the CSA Directives and guidelines governing standardization and are available on the Current Standards Activities page at standardsactivities.csa.ca.
- 5) *This Standard is subject to review five years from the date of publication. Suggestions for its improvement will be referred to the appropriate committee. To submit a proposal for change, please send the following information to inquiries@csagroup.org and include “Proposal for change” in the subject line:*
 - a) *Standard designation (number);*
 - b) *relevant clause, table, and/or figure number;*
 - c) *wording of the proposed change; and*
 - d) *rationale for the change.*

Z902-15

Blood and blood components

0 Introduction

This Standard has been prepared to maintain and enhance the safety, efficacy, and quality of blood collection, storage, processing, and transfusion. The requirements set out in this Standard are the minimum criteria for acceptable performance and may be exceeded in practice. It should be noted that activities covered within this Standard can also be subject to federal, provincial, territorial, or local laws and regulations. Additional national and international standards may be used to specific activities or functions within a health care facility, for example ISO 15189.

This Standard is not intended to replace detailed specifications and operating procedures; rather, the principles and criteria outlined in this Standard should be used in maintaining and preparing specifications and operating procedures.

Throughout this Standard, the term “blood component” refers to a therapeutic component of blood intended for transfusion (e.g., red cells, granulocytes, platelets, plasma) that can be prepared using conventional blood bank methodology. Such methods may include centrifugation, filtration, freezing, or other means of separating out the desired component. The term is also applied to whole blood.

Although this Standard centres on blood components, it is recognized that some hospital transfusion services also manage blood products as part of their responsibilities. Starting with the second edition, this Standard has included requirements for transfusion services that manage blood products so that procedures are appropriately consistent between the two types of blood-derived materials. For a facility or department that manages blood products but not blood components, such as a hospital pharmacy, the requirements of this Standard may be used as a reference in developing procedures for the management of blood products.

This Standard was developed by a Technical Committee representing a balance of interests that include health care professionals as well as representatives of the federal, provincial, and territorial governments, user groups, and blood centres. In developing this Standard, the Technical Committee extensively consulted equivalent standards in Canada and other jurisdictions, including the American Association of Blood Banks’ *Standards for Blood Banks and Transfusion Services* and the Canadian Society for Transfusion Medicine’s *Standards for Hospital Transfusion Services*. Differences from these standards, where they occur, represent the Technical Committee’s decisions based on Canadian practice and current scientific knowledge.

1 Scope

1.1

This Standard provides management requirements for facilities that collect, process, store, and use human blood components for transfusion. It addresses issues of safety, efficacy, and quality for recipients, safety of donors, management of blood components, and safety of facility personnel and others who are exposed to or potentially affected by blood components.

1.2

This Standard applies to blood centres and transfusion services and to any other organization that collects, processes, stores, or uses human blood components for transfusion.

1.3

It also includes requirements for the storage and use of blood products, when such products are within the responsibility of an organization that is covered by this Standard.

Note: *While this Standard does not specifically apply to organizations that manage blood products but not blood components (e.g., a hospital pharmacy), these organizations are encouraged to review the relevant requirements for blood products and incorporate them as appropriate into their procedures.*

1.4

As a management standard, this Standard is not intended to replace detailed specifications and operating procedures; rather, it is intended for use in their preparation. It includes requirements for policies and procedures, quality management, personnel, physical plant, and equipment. In addition, this Standard outlines specific requirements to be included in the facility's operating procedures for the following activities:

- a) donor selection for allogeneic blood collection;
- b) collection of blood components for transfusion;
- c) preparation of blood components;
- d) testing and labelling of blood components;
- e) release, storage, packing, and transportation;
- f) requests, pre-transfusion testing, selection of components, and acceptance criteria;
- g) transfusion;
- h) autologous blood collection and transfusion;
- i) apheresis donation;
- j) transfusion service responsibilities regarding blood products used in the facility;

Note: *This Item refers to blood products that are managed directly through the transfusion service, as opposed to those managed by other services, e.g. the pharmacy.*

- k) directed donations and designated donations;
- l) pre-assessed donor programs;
- m) home transfusion;
- n) adverse event monitoring and corrective action;
- o) removal of unsafe components and donors from the blood supply;
- p) record management; and
- q) validation and maintenance of computer systems.

1.5

This Standard does not include requirements for activities associated with

- a) the collection of plasma for use in the manufacture of plasma products; and
- b) the processing, manufacture, or commercial distribution of blood products, including solvent detergent plasma.

Note: *Plasma for use in the manufacture of a drug for human use is covered under the Blood Regulations.*

1.6

In this Standard, "shall" is used to express a requirement, i.e., a provision that the user is obliged to satisfy in order to comply with the standard; "should" is used to express a recommendation or that

which is advised but not required; and “may” is used to express an option or that which is permissible within the limits of the Standard.

Notes accompanying clauses do not include requirements or alternative requirements; the purpose of a note accompanying a clause is to separate from the text explanatory or informative material.

Notes to tables and figures are considered part of the table or figure and may be written as requirements.

Annexes are designated normative (mandatory) or informative (non-mandatory) to define their application.

2 Reference publications

This Standard refers to the following publications, and where such reference is made, it shall be to the edition listed below, including all amendments published thereto.

CSA Group

CAN/CSA-C22.2 No. 60601-1:14

Medical electrical equipment — Part 1: General requirements for basic safety and essential performance

Z317.10-15

Handling of waste materials in health care facilities and veterinary health care facilities

Government of Canada

Food and Drugs Act, Chapter F-27 of the Revised Statutes of Canada, 1985

Nuclear Safety and Control Act (1997, c.9)

Health Canada

Blood Regulations, SOR/2013-178, 2013-10-23

Guidance Document: Blood Regulations, Health Products and Foods Branch, 2014-05-12

Blood Establishment Licence Amendment Requirements for Information Technology Submissions. Biologics and Genetic Therapies Directorate. October 2002.

Guideline for Investigation of Suspected Transfusion Transmitted Bacterial Contamination. Canada Communicable Disease Report (CCDR). Supplement, Vol. 34S1, January 2008.

Infection Control Guidelines: Handwashing, Cleaning, Disinfection and Sterilization in Health Care. Canada Communicable Disease Report (CCDR). Supplement, vol. 24S8, December 1998.

Medical Devices Regulations, SOR/98-282

Other publications

American Association of Blood Banks

Standards for Blood Banks and Transfusion Services, 29th ed. 2014.